Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

A new drug for people who have one of the worst forms of multiple sclerosis aims to make treatment much easier for patients. Ocrevus is a medicine commonly used to treat primary progressive MS ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

National Multiple Sclerosis Society: "FDA Approves Ocrevus™ (ocrelizumab) for People with Primary Progressive MS or Relapsing MS -- First Disease-Modifying Therapy for Primary Progressive MS ...

Ocrevus Zunovo, to patients with progressive types of multiple sclerosis (M.S.). Multiple sclerosis is a neurological ...

"Thus, progression is present in most, if not all, patients with multiple sclerosis, regardless of where they are ...

Ocrevus (ocrelizumab ... cases of late onset (also called later-onset) multiple sclerosis have been documented in people in ...

Multiple Sclerosis Trust (UK): “Ocrevus.” MS Society (UK): “Targeting B cells to treat progressive MS.” Fiona Gupta, MD, neurologist and director of wellness and health, Icahn School of ...

Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and ...

New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.